Compass Therapeutics, Inc. (CMPX) Stock Forecast
CMPX analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.47 / 5 from 15 analysts
- Price target
- $5.45 average of analyst targets
- Upside to target
- +534.3% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.12
- 52-week range
- $0.86 – $6.69
CMPX analyst ratings
15 analystsNumber of analysts at each rating.
CMPX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CMPX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.13 | −$0.15 | −$0.10 | −$0.08 | −58.0% | 11 |
| Current fiscal year (2026) | −$0.48 | −$0.55 | −$0.40 | −$0.42 | −15.4% | 11 |
| Next fiscal year (2027) | −$0.54 | −$0.66 | −$0.38 | −$0.48 | −11.0% | 10 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CMPX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 14 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 14 |
| Next fiscal year (2027) | $6.5M | $0 | $61.3M | 0.0% | 14 |
CMPX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CMPX revenue: reported and forecast
CMPX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.11 | −$0.11 | −$0.13 | −$0.13 | −$0.13 | +18.8% | 2 up · 0 down |
| Current fiscal year (2026) | −$0.44 | −$0.43 | −$0.49 | −$0.49 | −$0.48 | +11.0% | 3 up · 0 down |
| Next fiscal year (2027) | −$0.46 | −$0.46 | −$0.54 | −$0.54 | −$0.54 | +16.3% | 2 up · 7 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CMPX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CMPX beat in 6 of 12.
What analysts expect from CMPX
15 analysts cover Compass Therapeutics; their consensus rating is buy (4.47 on a 1–5 scale, where 5 is a strong buy). The average price target is $5.45, 534.3% above the latest close of $0.86. Analysts expect earnings of −$0.48 per share for 2026, −15.4% from a year earlier. For 2027 the average estimate is −$0.54 per share on revenue of $6.5 million. Compass Therapeutics beat the EPS estimate in 6 of the last 12 quarters.
Related: CMPX income statement, CMPX key metrics, CMPX chart. See the CMPX stock overview for the latest quote and news.
CMPX forecast FAQ
What is Compass Therapeutics's price target?
The average analyst price target for Compass Therapeutics is $5.45, 534.3% above the latest close of $0.86.
Is Compass Therapeutics a buy, hold or sell?
Of 15 analysts covering Compass Therapeutics, 10 rate it a strong buy, 2 a buy, 3 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Compass Therapeutics's EPS forecast?
Analysts forecast −$0.48 per share for 2026 (range −$0.55 to −$0.40); for 2027 the estimate is −$0.54.
When does Compass Therapeutics report earnings?
Compass Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026; the EPS estimate is $-0.12.
Does Compass Therapeutics usually beat earnings estimates?
Compass Therapeutics reported EPS at or above the analyst estimate in 6 of the last 12 quarters.